Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288626 · ClinicalTrials.gov registry record · Phase 2
High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00288626 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 25 participants.
The verdict
NCT00288626, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of a new treatment for multiple sclerosis (MS), a serious disease in which the immune system attacks the brain and spinal cord. MS can be progressive and severe and lead to significant disability. The study treatment involves the use of high-dose chemotherapeutic drugs to suppress the immune system. The participant's own (autologous) blood-forming (hematopoietic, CD34+) stem cells are collected before the chemotherapy is given, and then transplanted back into the body following treatment. Transplantation of autologous hematopoietic stem cells is required to prevent very prolonged periods of low blood cell counts after the high-dose chemotherapy.
Interventions
- DRUG Granulocyte-colony stimulating factor (G-CSF) and prednisone
- DRUG Carmustine, etoposide, cytarabine, and melphalan (BEAM)
- PROCEDURE Autologous hematopoietic stem cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-07 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00288626
The ClinicalTrials.gov registry entry for NCT00288626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Granulocyte-colony stimulating factor (G-CSF) and prednisone is the first listed.
NCT00288626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00288626 about?
NCT00288626 is a clinical study titled "High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study". The purpose of this study is to determine the effectiveness of a new treatment for multiple sclerosis (MS), a serious disease in which the immune system attacks the brain and spinal cord. MS can be progressive and severe and lead to significant disability. The study treatment involves the use of hig...
What is the current status of trial NCT00288626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-07. Estimated completion is 2015-11.
What interventions are being tested in trial NCT00288626?
The interventions under investigation include: Granulocyte-colony stimulating factor (G-CSF) and prednisone (DRUG), Carmustine, etoposide, cytarabine, and melphalan (BEAM) (DRUG), Autologous hematopoietic stem cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00288626?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.